Egilius Spierings
Neurology · Wellesley Hills, MANPI 1487748703
Payments from drug & device makers
Across 1,009 payments — averaging $2796.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$824K
- Teva Pharmaceuticals USA, Inc.$384K
- H. Lundbeck A S$318K
- AbbVie$227K
- Eli Lilly$179K
- Biohaven Pharmaceutical Holding Company Ltd.$169K
- plus $720K from 11 others
Across 8 payments — averaging $2026.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$14K
- Eli Lilly$3K
- Teva Pharmaceuticals USA, Inc.$56
What the payments were for
- Consulting fees$22,5233%
- Speaking & faculty fees$620,46291%
- Grants$880%
- Travel & lodging$21,9463%
- Food & beverage$14,3282%
- Education$2400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 75 | $824,308 |
| Teva Pharmaceuticals USA, Inc. | 176 | $384,122 |
| H. Lundbeck A S | 26 | $317,943 |
| AbbVie(2 entities) | 237 | $227,448 |
| Eli Lilly | 4 | $179,134 |
| Biohaven Pharmaceutical Holding Company Ltd. | 34 | $168,811 |
| Novartis | 8 | $164,435 |
| Pfizer | 43 | $135,946 |
| Lilly USA, LLC | 187 | $129,323 |
| Ironwood Pharmaceuticals, Inc | 17 | $118,769 |
| Lundbeck LLC | 102 | $85,778 |
| Amgen | 78 | $76,420 |
| Biodelivery Sciences International, Inc. | 13 | $9,017 |
| Collegium Pharmaceutical, Inc. | 4 | $224 |
| Impel Pharmaceuticals Inc. | 1 | $80 |
| Sunovion Pharmaceuticals Inc. | 3 | $71 |
| Boston Scientific | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,821,847 in reported general payments places this provider in the 95th percentile of 761 neurology providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BotoxOnabotulinumtoxina | 63 | $80,152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox | $227,448 | $80,15263 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 761 neurology providers in Massachusetts.
Other neurology in Wellesley Hills
- Stephanie RutrickBoston$31.4M
- Scott PlotkinBoston$26.3M
- Patrick WenBoston$18.2M
- James BerryBoston$8.9M
- Isabel Arrillaga-RomanyBoston$8.2M
- Donald MarksPlymouth$7.8M
- Mahmut GurolBoston$7.4M
- Gad MarshallBoston$6M
- Shawn MurphyBoston$5.9M
- Suma BabuBoston$5.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.